TG Therapeutics (TGTX) Debt/Equity Ratio: History & Chart

TG Therapeutics, Inc.(TGTX)

Biotechnology · Morrisville, NY

$52.05-1.86 (-3.46%)

Delayed quote: Oct 6, 2026, 2:05 PM EDT

About TG Therapeutics, Inc.

Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.

Morrisville, NY

399 employees

www.tgtherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael S. Weiss

View full financials

TGTX Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

1.25

DEBT TO EQUITY RATIO AVG TTM

0.86

DEBT TO EQUITY RATIO AVG 3Y

0.87

DEBT TO EQUITY RATIO AVG 5Y

0.75

DEBT TO EQUITY RATIO AVG 10Y

0.48

DEBT TO EQUITY RATIO AVG 15Y

0.35

DEBT TO EQUITY RATIO AVG 20Y

0.19

CURRENT VS TTM AVG

+45.93%

CURRENT VS 3Y AVG

+42.75%

CURRENT VS 5Y AVG

+65.54%

CURRENT VS 10Y AVG

+157.58%

CURRENT VS 15Y AVG

+259.49%

CURRENT VS 20Y AVG

+574.82%

SECTOR MEDIAN · HEALTHCARE

0.11

median of 766 covered companies

CURRENT VS SECTOR MEDIAN

+1035.37%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
TG Therapeutics, Inc. (TGTX)	$7.97B	1.25	0.86	0.87	0.75
Caris Life Sciences, Inc. (CAI)vs ›	$7.89B	0.76	0.66	0.66	1.58
Praxis Precision Medicines, Inc. (PRAX)vs ›	$7.70B	0.00	0.00	0.02	0.02
Cytokinetics, Incorporated (CYTK)vs ›	$7.62B	N/A	1.17	1.33	0.91
HealthEquity, Inc. (HQY)vs ›	$7.61B	0.49	0.50	0.49	0.55
Oscar Health, Inc. (OSCR)vs ›	$8.35B	0.21	0.37	0.36	0.29
Hinge Health, Inc. (HNGE)vs ›	$7.57B	0.02	0.03	0.03	0.03
Kymera Therapeutics, Inc. (KYMR)vs ›	$8.59B	0.05	0.08	0.10	0.09
Ionis Pharmaceuticals, Inc. (IONS)vs ›	$7.33B	5.50	3.88	3.48	2.79
Arrowhead Pharmaceuticals, Inc. (ARWR)vs ›	$8.73B	1.86	2.69	1.75	1.18

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

TG Therapeutics, Inc. (TGTX)

$7.97B

1.25

0.86

0.87

0.75

Caris Life Sciences, Inc. (CAI)vs ›

$7.89B

0.76

0.66

1.58

Praxis Precision Medicines, Inc. (PRAX)vs ›

$7.70B

0.00

0.02

Cytokinetics, Incorporated (CYTK)vs ›

$7.62B

N/A

1.17

1.33

0.91

HealthEquity, Inc. (HQY)vs ›

$7.61B

0.49

0.50

0.49

0.55

Oscar Health, Inc. (OSCR)vs ›

$8.35B

0.21

0.37

0.36

0.29

Hinge Health, Inc. (HNGE)vs ›

$7.57B

0.02

0.03

Kymera Therapeutics, Inc. (KYMR)vs ›

$8.59B

0.05

0.08

0.10

0.09

Ionis Pharmaceuticals, Inc. (IONS)vs ›

$7.33B

5.50

3.88

3.48

2.79

Arrowhead Pharmaceuticals, Inc. (ARWR)vs ›

$8.73B

1.86

2.69

1.75

1.18

Debt to Equity Ratio FAQ

What is the debt to equity ratio for TG Therapeutics, Inc. (TGTX)?

The debt to equity ratio for TGTX stock is 1.25.

Is TG Therapeutics, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 1.25 is 66% above its 5-year average of 0.75, around the middle of its 5-year range (0.09–3.94).

What is the TTM average debt to equity ratio for TG Therapeutics, Inc. (TGTX)?

The TTM average debt to equity ratio for TGTX stock is 0.86.

What is the 3Y average debt to equity ratio for TG Therapeutics, Inc. (TGTX)?

The 3Y average debt to equity ratio for TGTX stock is 0.87.

What is the 5Y average debt to equity ratio for TG Therapeutics, Inc. (TGTX)?

The 5Y average debt to equity ratio for TGTX stock is 0.75.

What is the 10Y average debt to equity ratio for TG Therapeutics, Inc. (TGTX)?

The 10Y average debt to equity ratio for TGTX stock is 0.48.

What is the 15Y average debt to equity ratio for TG Therapeutics, Inc. (TGTX)?

The 15Y average debt to equity ratio for TGTX stock is 0.35.

What is the 20Y average debt to equity ratio for TG Therapeutics, Inc. (TGTX)?

The 20Y average debt to equity ratio for TGTX stock is 0.19.

DATE	DEBT TO EQUITY RATIO
2026-06-30	1.25
2026-03-31	1.29
2025-12-31	0.40
2025-09-30	0.42
2025-06-30	0.92
2025-03-31	1.07
2024-12-31	1.14
2024-09-30	1.32
2024-06-30	0.63
2024-03-31	0.70
2023-12-31	0.69
2023-09-30	0.67
2023-06-30	2.69
2023-03-31	3.94
2022-12-31	1.42
2022-09-30	0.82
2022-06-30	0.62
2022-03-31	0.46
2021-12-31	0.33
2021-09-30	0.09
2021-06-30	0.09
2021-03-31	0.09
2020-12-31	0.08
2020-09-30	0.24
2020-06-30	0.21
2020-03-31	-30.27
2019-12-31	1.06
2019-09-30	-0.06
2019-06-30	2.87
2019-03-31	1.96
2018-12-31	0.00
2018-09-30	0.00
2018-06-30	0.00
2018-03-31	0.00
2017-12-31	0.00
2017-09-30	0.00
2017-06-30	0.00
2017-03-31	0.00
2016-12-31	0.00
2016-09-30	0.00
2016-06-30	0.00
2016-03-31	0.00
2015-12-31	0.00
2015-09-30	0.00
2015-06-30	0.00
2015-03-31	0.00
2014-12-31	0.00
2014-09-30	0.00
2014-06-30	0.00
2014-03-31	0.00
2013-12-31	0.02
2013-09-30	0.07
2013-06-30	0.30
2013-03-31	0.21
2012-12-31	0.20
2012-09-30	0.54
2012-06-30	0.46
2012-03-31	0.46
2011-12-31	0.51
2011-09-30	-59.76
2011-06-30	-8.14
2011-03-31	-14.51
2010-12-31	-3.51
2010-09-30	-3.25
2010-06-30	-3.20
2010-03-31	-2.45
2009-12-31	-0.29
2009-09-30	-0.27
2009-06-30	-0.27
2009-03-31	-0.32
2008-12-31	-0.29
2008-09-30	-0.01
2008-06-30	0.00
2008-03-31	0.00
2007-12-31	0.00
2007-09-30	0.00
2007-06-30	0.00
2007-03-31	0.00
2006-12-31	0.00
2006-09-30	0.00
2006-06-30	0.00
2006-03-31	0.00
2005-12-31	0.00
2005-09-30	0.00
2005-06-30	0.39
2005-03-31	0.00
2004-12-31	0.00
2004-09-30	0.00
2004-06-30	0.00
2004-03-31	0.00
2003-12-31	0.00
2003-09-30	-0.10
2003-06-30	0.03
2003-03-31	0.02
2002-12-31	-2.45
2002-09-30	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

1.25

2026-03-31

1.29

2025-12-31

0.40

2025-09-30

0.42

2025-06-30

0.92

2025-03-31

1.07

2024-12-31

1.14

2024-09-30

1.32

2024-06-30

0.63

2024-03-31

0.70

2023-12-31

0.69

2023-09-30

0.67

2023-06-30

2.69

2023-03-31

3.94

2022-12-31

1.42

2022-09-30

0.82

2022-06-30

0.62

2022-03-31

0.46

2021-12-31

0.33

2021-09-30

0.09

2021-06-30

0.09

2021-03-31

0.09

2020-12-31

0.08

2020-09-30

0.24

2020-06-30

0.21

2020-03-31

-30.27

2019-12-31

1.06

2019-09-30

-0.06

2019-06-30

2.87

2019-03-31

1.96

2018-12-31

0.00

2018-09-30

0.00

2018-06-30

0.00

2018-03-31

0.00

2017-12-31

0.00

2017-09-30

0.00

2017-06-30

0.00

2017-03-31

0.00

2016-12-31

0.00

2016-09-30

0.00

2016-06-30

0.00

2016-03-31

0.00

2015-12-31

0.00

2015-09-30

0.00

2015-06-30

0.00

2015-03-31

0.00

2014-12-31

0.00

2014-09-30

0.00

2014-06-30

0.00

2014-03-31

0.00

2013-12-31

0.02

2013-09-30

0.07

2013-06-30

0.30

2013-03-31

0.21

2012-12-31

0.20

2012-09-30

0.54

2012-06-30

0.46

2012-03-31

0.46

2011-12-31

0.51

2011-09-30

-59.76

2011-06-30

-8.14

2011-03-31

-14.51

2010-12-31

-3.51

2010-09-30

-3.25

2010-06-30

-3.20

2010-03-31

-2.45

2009-12-31

-0.29

2009-09-30

-0.27

2009-06-30

-0.27

2009-03-31

-0.32

2008-12-31

-0.29

2008-09-30

-0.01

2008-06-30

0.00

2008-03-31

0.00

2007-12-31

0.00

2007-09-30

0.00

2007-06-30

0.00

2007-03-31

0.00

2006-12-31

0.00

2006-09-30

0.00

2006-06-30

0.00

2006-03-31

0.00

2005-12-31

0.00

2005-09-30

0.00

2005-06-30

0.39

2005-03-31

0.00

2004-12-31

0.00

2004-09-30

0.00

2004-06-30

0.00

2004-03-31

0.00

2003-12-31

0.00

2003-09-30

-0.10

2003-06-30

0.03

2003-03-31

0.02

2002-12-31

-2.45

2002-09-30

0.00

Debt to Equity Ratio: 1.25

TGTX Debt to Equity Ratio

TGTX Average Debt to Equity Ratio Chart

TGTX Current vs Average Debt to Equity Ratio Chart

TGTX Debt to Equity Ratio Metrics

TGTX Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

TGTX Debt to Equity Ratio History

Related Metrics